Table 1 The prognostic values of immune landscape markers in EC

MAGE-A11

− [63]

N/A

N/A

+ [63]

N/A

N/A

NY-ESO-1

N/A

N/A

N/A

N/A

N/A

Vaccination:− [24]

TMB

N/A

N/A

N/A

N/A

N/A

PD-1 inhibition: + [18]

MANA

N/A

N/A

N/A

N/A

N/A

PD-1 inhibition: + [18]

PD-L1

N/A

N/A

N/A

N/A

N/A

PD-1 inhibition: + [18]

PD-1

N/A

+ [67]

N/A

+ [67]

N/A

N/A

CTLA-4

− [28]

N/A

N/A

N/A

N/A

N/A

IDO1

− [32, 70]

N/A

N/A

N/A

− [68]

N/A

PD-L1 + IDO1

− [68, 69]

N/A

N/A

N/A

− [69]

N/A

VISTA

+ [27]

N/A

N/A

N/A

N/A

N/A

TGF-β

N/A

N/A

N/A

N/A

− [72]

N/A

TGF-β + IL-10

N/A

+ [71]

N/A

N/A

N/A

N/A

IL-6

N/A

N/A

N/A

N/A

− [50]

N/A

CD80 or CD86

N/A

− [71, 73]

− [71, 73]

N/A

N/A

N/A

CD1a⁺ cells

N/A

N/A

− [73]

N/A

N/A

N/A

CD8⁺ TILs

+ [75]

N/A

N/A

− [75]

+ [75]

N/A

CD8⁺/Foxp3⁺ ratio

+ [29]

N/A

N/A

N/A

N/A

N/A

CCL4^highCCL20^low

+ [52]

N/A

N/A

N/A

N/A

N/A

M2-like TAMs

− [48, 49]

N/A

N/A

N/A

N/A

N/A

MDSCs

N/A

+ [50, 51]

N/A

N/A

− [50]

N/A